Royal Bank of Canada
UNCY icon

Royal Bank of Canada’s Unicycive Therapeutics UNCY Stock Holding History

Royal Bank of Canada’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
+377
New +$2.47K ﹤0.01% 6764
2022
Q3 		– Sell
-500
Closed -$4K – 7884
2022
Q2 		$4K Buy
+500
New +$4.78K ﹤0.01% 6766

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's UNCY Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Unicycive Therapeutics (UNCY) in Q1 2026: 377 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #6764 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in UNCY as recently as Q2 2022.

Royal Bank of Canada first reported a position in UNCY in Q2 2022 and has held it in 2 quarters since. The position peaked at $4K in Q2 2022. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Royal Bank of Canada held 377 shares of Unicycive Therapeutics worth $2K as of Q1 2026.
  • Unicycive Therapeutics was a new Royal Bank of Canada position in Q1 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6764 holding.
  • Royal Bank of Canada first reported a position in Unicycive Therapeutics in Q2 2022 and has held it in 2 quarters since.
  • Royal Bank of Canada's Unicycive Therapeutics position peaked at $4K in Q2 2022.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.